SARS-CoV-2 Mutations and their Viral Variants

dc.contributor.authorCosar, Begum
dc.contributor.authorKaragulleoglu, Zeynep Yagmur
dc.contributor.authorUnal, Sinan
dc.contributor.authorInce, Ahmet Turan
dc.contributor.authorUncuoglu, Dilruba Beyza
dc.contributor.authorTuncer, Gizem
dc.contributor.authorKilinc, Bugrahan Regaip
dc.date.accessioned2025-10-29T11:29:28Z
dc.date.issued2022
dc.departmentGebze Teknik Üniversitesi
dc.description.abstractMutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occur spontaneously during replication. Thousands of mutations have accumulated and continue to since the emergence of the virus. As novel mutations continue appearing at the scene, naturally, new variants are increasingly observed.Since the first occurrence of the SARS-CoV-2 infection, a wide variety of drug compounds affecting the binding sites of the virus have begun to be studied. As the drug and vaccine trials are continuing, it is of utmost importance to take into consideration the SARS-CoV-2 mutations and their respective frequencies since these data could lead the way to multi-drug combinations. The lack of effective therapeutic and preventive strategies against human coronaviruses (hCoVs) necessitates research that is of interest to the clinical applications.The reason why the mutations in glycoprotein S lead to vaccine escape is related to the location of the mutation and the affinity of the protein. At the same time, it can be said that variations should occur in areas such as the receptor-binding domain (RBD), and vaccines and antiviral drugs should be formulated by targeting more than one viral protein.
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUuml;BI?TAK) [18AG020, 2247-C]
dc.description.sponsorshipThe preparation of this review was supported by the Scientific and Technological Research Council of Turkey (TUBITAK) , Project #18AG020 and TUBITAK Intern Researchers (STAR) Program #2247-C.
dc.identifier.doi10.1016/j.cytogfr.2021.06.001
dc.identifier.endpage22
dc.identifier.issn1359-6101
dc.identifier.issn1879-0305
dc.identifier.orcid0000-0003-4897-9388
dc.identifier.orcid0000-0003-0359-6308
dc.identifier.orcid0000-0001-9433-2054
dc.identifier.orcid0000-0002-8988-3641
dc.identifier.orcid0000-0002-2975-8961
dc.identifier.orcid0000-0001-5892-5928
dc.identifier.pmid34580015
dc.identifier.scopus2-s2.0-85115962112
dc.identifier.scopusqualityQ1
dc.identifier.startpage10
dc.identifier.urihttps://doi.org/10.1016/j.cytogfr.2021.06.001
dc.identifier.urihttps://hdl.handle.net/20.500.14854/11123
dc.identifier.volume63
dc.identifier.wosWOS:000767550600002
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofCytokine & Growth Factor Reviews
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20251020
dc.subjectCOVID-19
dc.subjectMutation
dc.subjectReceptor-binding domain
dc.subjectSARS-CoV-2
dc.subjectSpike protein
dc.subjectViral variants
dc.titleSARS-CoV-2 Mutations and their Viral Variants
dc.typeReview Article

Dosyalar